Takeda Pharmaceutical Co Ltd
TAK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395064
In the last 90 days, Takeda Pharmaceutical Co Ltd insiders filed 0 open-market purchases and 19 sales; 379 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; no superinvestor holds it.
Other share classesTKPHF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $13.1M in total
- 19
- 13F holdersQ2 2026, +26 vs. previous quarter
- 379
- 13F valueReported value at the end of Q2 2026
- $1.67B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TAK, Q2 2026
No superinvestor reported holding TAK at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Takeda Pharmaceutical Co Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)9:12 PM ET | Sep 14 | 1 day | Duprey Lauren RusckowskiChief Transformation Officer | SSaleAmerican Depositary Shares | −34.5K | $18.54 | −$640.3K | −15.3%191.5K after | |
| Sep 3, 2026 (view filing)9:49 PM ET | Sep 2 | 1 day | Plump Andrew StewartPresident, R&D | SSaleAmerican Depositary Shares | −116.2K | $18.49 | −$2.15M | −44.4%145.5K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Plump Andrew StewartPresident, R&D | SSaleAmerican Depositary Shares | −19.7K | $18.49 | −$363.3K | −7.0%261.7K after | 10b5-1 |
| Aug 19, 2026 (view filing)4:15 PM ET | Aug 18 | 1 day | Greenway Nicola Deidre PetalChief Human Resources Officer | SSaleAmerican Depositary Shares | −13.0K | $18.11 | −$235.1K | −24.5%40.0K after | |
| Aug 12, 2026 (view filing)9:54 PM ET | Aug 10 | 2 days | Farajallah Awny Samaan BotrosChief Medical Officer | SSaleAmerican Depositary Shares | −14.0K | $17.10 | −$239.5K | −10.8%116.2K after | |
| Aug 12, 2026 (view filing)9:53 PM ET | Aug 10 | 2 days | Ibrahim Ramy Riad AhmedPresident, PDT BU | SSaleAmerican Depositary Shares | −7.28K | $17.10 | −$124.4K | −6.6%102.6K after | |
| Aug 12, 2026 (view filing)9:53 PM ET | Aug 10 | 2 days | Pacheco Rhonda JanicePresident, U.S. Business Unit | SSaleAmerican Depositary Shares | −16.9K | $17.10 | −$289.0K | −8.5%182.5K after | |
| Aug 12, 2026 (view filing)9:51 PM ET | Aug 10 | 2 days | Duprey Lauren RusckowskiChief Transformation Officer | SSaleAmerican Depositary Shares | −47.6K | $17.10 | −$813.7K | −17.4%226.1K after | |
| Aug 12, 2026 (view filing)9:50 PM ET | Aug 10 | 2 days | Plump Andrew StewartPresident, R&D | SSaleAmerican Depositary Shares | −165.4K | $17.10 | −$2.83M | −17.7%766.6K after | |
| Aug 12, 2026 (view filing)9:46 PM ET | Aug 10 | 2 days | Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev | SSaleAmerican Depositary Shares | −23.0K | $17.10 | −$392.6K | −11.5%177.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Takeda Pharmaceutical Co Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital Research Global Investors | 19,297,680 | $309.3M | 0.04% | +193,461+1.0% | Added |
| FMR LLC | 9,599,302 | $153.9M | 0.01% | +2,481,816+34.9% | Added |
| Morgan Stanley | 6,994,924 | $112.1M | 0.01% | +525,324+8.1% | Added |
| Adage Capital Partners GP, L.L.C. | 6,050,771 | $97.0M | 0.14% | −374,213−5.8% | Reduced |
| Goldman Sachs Group Inc | 5,125,032 | $82.2M | 0.01% | −493,696−8.8% | Reduced |
| Brandes Investment Partners, LP | 4,539,347 | $72.8M | 0.51% | +108,705+2.5% | Added |
| Arrowstreet Capital, Limited Partnership | 3,732,924 | $59.8M | 0.03% | +616,613+19.8% | Added |
| BlackRock, Inc. | 3,688,166 | $59.1M | 0.00% | +511,745+16.1% | Added |
| Renaissance Technologies LLC | 2,568,000 | $41.2M | 0.06% | −421,100−14.1% | Reduced |
| Qube Research & Technologies Ltd | 2,207,432 | $35.4M | 0.04% | +2,207,432 | New |